Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04098250 · ClinicalTrials.gov registry record · Phase 2

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

A Phase 2 study of Post-Traumatic Headache, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
5
Study locations

NCT04098250: Completed Phase 2 study of Post-Traumatic Headache, sponsored by Mayo Clinic.

NCT04098250 is a Phase 2 study of Post-Traumatic Headache that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 173-participant average among 11 other Post-Traumatic Headache trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04098250, a Phase 2 study of Post-Traumatic Headache, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
5
Study locations

Study Summary

This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence. The objective of the clinical trial component of the Focused Program is to determine whether intervention with erenumab is an effective treatment for PTH attributed to mTBI.

Primary Outcome

The number of days where subjects experienced moderate-to-severe headaches. This was measured at baseline, 9, 10, 11 and 12 weeks after administration of first dose of erenumab 140 mg or placebo. The change from baseline to week 12 is reported.

Conditions Studied

Post-Traumatic Headache

Interventions

  • OTHER Placebo
  • DRUG Erenumab

Study Locations (5)

Arizona

  • Phoenix VA Health Care System - Phoenix
  • Mayo Clinic - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2021-01-04
Est. Completion 2024-01-10
Phase Phase 2
Mayo Clinic

2,844 total trials

What the finished NCT04098250 record still lists

NCT04098250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 173-participant average among 11 other Post-Traumatic Headache trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Post-Traumatic Headache appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04098250 lists 5 locations in 3 states (Arizona, Florida, Minnesota).

Frequently Asked Questions

What is clinical trial NCT04098250 about?

NCT04098250 is a clinical study titled "Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH". This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence. The objective of th...

What is the current status of trial NCT04098250?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-01-04. Estimated completion is 2024-01-10.

What conditions does trial NCT04098250 study?

This clinical trial studies the following conditions: Post-Traumatic Headache.

What interventions are being tested in trial NCT04098250?

The interventions under investigation include: Placebo (OTHER), Erenumab (DRUG).

Who is sponsoring clinical trial NCT04098250?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04098250 being conducted?

This trial has 5 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post-Traumatic Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04098250's enrollment target sits among peer trials

6 12th of 11 the lowest of 11 other Post-Traumatic Headache trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post-Traumatic Headache trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04098250, the US trial registry maintained by the National Library of Medicine. NCT04098250 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.